Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;27(1):147-150.
doi: 10.1038/cr.2016.77. Epub 2016 Jun 21.

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

Zhenkun Na  1 , Siok Ping Yeo  2 , Sakshibeedu R Bharath  1 , Matthew W Bowler  3   4 , Esra Balıkçı  1 , Cheng-I Wang  2 , Haiwei Song  1   5
Affiliations

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

Zhenkun Na et al. Cell Res. 2017 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structural basis for the blockade of hPD-1/hPD-L1 interaction by pembrolizumab. (A) Overall structure of the hPD-1/pembrolizumab Fab complex. hPD-1 is shown in light blue, and the light and heavy chains of Fab are in wheat and pale green, respectively. The CDR loops and the β-strands of pembrolizumab that are involved in interactions are labeled. (B) View of sub-interface I in hPD-1/pembrolizumab Fab complex. Residues involved in the interaction are shown as sticks and labeled. Hydrogen bonds are shown in dash lines. (C) View of sub-interface II in hPD-1/pembrolizumab Fab complex. (D) Sequence alignment of the C′D loop in ectodomains of PD-1. Secondary structural elements of hPD-1 are shown on top of the alignment while those of mPD-1 are shown at the bottom. (E) ELISA data showing the binding of pembrolizumab to hPD-1 or hPD-1 mutants, and mPD-1. (F) Superposition of the hPD-1/pembrolizumab Fab complex with hPD-1/hPD-L1. hPD-L1 is shown in magenta. For simplicity, only hPD-1 in hPD-1/pembrolizumab Fab is shown in light blue.
See this image and copyright information in PMC

References

    1. Pardoll DM. Nat Rev Cancer 2012; 12:252–264. - PMC - PubMed
    1. Okazaki T, Chikuma S, Iwai Y, et al. Nat Immunol 2013; 14:1212–1218. - PubMed
    1. Hamid O, Robert C, David A, et al. N Engl J Med 2013; 369:134–144. - PMC - PubMed
    1. Rivoltini L, Carrabba M, Huber V, et al. Immunol Rev 2002; 188:97–113. - PubMed
    1. Riley JL. N Engl J Med 2013; 369:187–189. - PubMed

Publication types

MeSH terms